Bifogade filer
Grant from EU
Carl Johan Ivarsson Qlucore 1
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Qlucore was today informed that we have passed the evaluation phase for a prestigious grant of 27 MSEK to advance personalized cancer treatment.
Qlucore, a leader in software development for precision cancer diagnostics, have passed the evaluation phase for a prestigious grant of 27 MSEK to accelerate the clinical cancer diagnostics solutions for acute myeloid leukemia (AML) as well as bladder cancer.
During the project Qlucore will develop and then launch CE marked software for clinical cancer diagnostics for the two cancer types. The project stretches over four years, and the objectives are to develop solutions for use by clinical laboratories as well as solutions in collaboration with pharma companies, companion diagnostics (CDx).
The targeted cancer disease areas are important because both cancer types have multiple changes on the RNA level that can be utilized to improve diagnosis and treatment. However, today this information is not fully used to provide the right therapy for the right patient. The project aims to change this.
The recognition from the expert review panels of our solutions and the addressed clinical need further strengthens the belief in our strategic direction and our focus on solutions based on RNA. RNA-based solutions are gaining momentum, allowing for cancer classification using gene fusions and gene expression signatures. RNA-seq can reliably detect gene fusions and measure gene expression levels, thereby providing more insights into cancer biology.
The grant will strengthen the financial position of Qlucore. A formal grant agreement phase will now take place and from earlier calls we estimate that it will be concluded before the summer of 2024. The EIC Accelerator grant is awarded in tough competition.
For a medical device to be used in healthcare diagnostics, IVDR regulations require the device to have CE marking. For this project Qlucore will build on the significant investments done for the solutions for acute lymphoblastic leukemia - Qlucore Diagnostics BCP-ALL, both from a software technical point of view and a quality management system (QMS) point of view.
"We are clearly at the forefront of RNA-seq based modern clinical diagnostics. To receive this grant strengthens Qlucore financially as well as in the market," says Carl-Johan Ivarsson, CEO of Qlucore.
The intended customers are clinical laboratories in Europe in the first phase and the US market in the second phase. In parallel the objective is to use the solution for companion diagnostics (CDx) together with pharma companies.